SMI
14.215,30
PKT
+40,95
PKT
+0,29
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SMI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 24.04.14 | UBS Hold | Commerzbank AG | |
| 24.04.14 | Novartis buy | UBS AG | |
| 24.04.14 | ABB (Asea Brown Boveri) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 23.04.14 | Novartis buy | Société Générale Group S.A. (SG) | |
| 23.04.14 | Novartis buy | S&P Capital IQ | |
| 23.04.14 | Novartis Underweight | Barclays Capital | |
| 23.04.14 | Novartis buy | UBS AG | |
| 23.04.14 | Novartis Hold | Deutsche Bank AG | |
| 22.04.14 | UBS buy | S&P Capital IQ | |
| 22.04.14 | Novartis Neutral | JP Morgan Chase & Co. | |
| 17.04.14 | UBS buy | Citigroup Corp. | |
| 17.04.14 | UBS Hold | Kelper Cheuvreux | |
| 17.04.14 | Zurich Insurance overweight | JP Morgan Chase & Co. | |
| 17.04.14 | Novartis Neutral | JP Morgan Chase & Co. | |
| 17.04.14 | UBS buy | UBS AG | |
| 17.04.14 | Novartis buy | UBS AG | |
| 16.04.14 | Roche buy | Citigroup Corp. | |
| 16.04.14 | Nestlé Halten | Independent Research GmbH | |
| 16.04.14 | Roche overweight | JP Morgan Chase & Co. | |
| 16.04.14 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 16.04.14 | Roche overweight | Morgan Stanley | |
| 16.04.14 | Nestlé overweight | Morgan Stanley | |
| 16.04.14 | Nestlé Neutral | UBS AG | |
| 16.04.14 | Roche buy | UBS AG | |
| 16.04.14 | Roche overweight | Barclays Capital | |
| 15.04.14 | Nestlé Sell | S&P Capital IQ | |
| 15.04.14 | Roche kaufen | Independent Research GmbH | |
| 15.04.14 | Givaudan Outperform | Credit Suisse Group | |
| 15.04.14 | UBS Neutral | Goldman Sachs Group Inc. | |
| 15.04.14 | UBS buy | Goldman Sachs Group Inc. | |
| 14.04.14 | Roche buy | Jefferies & Company Inc. | |
| 14.04.14 | Novartis Hold | Jefferies & Company Inc. | |
| 14.04.14 | Givaudan overweight | JP Morgan Chase & Co. | |
| 14.04.14 | Nestlé overweight | JP Morgan Chase & Co. | |
| 14.04.14 | Givaudan Underweight | Barclays Capital | |
| 14.04.14 | Givaudan Underweight | Barclays Capital | |
| 14.04.14 | Givaudan buy | UBS AG | |
| 11.04.14 | Givaudan Neutral | Merrill Lynch & Co., Inc. | |
| 11.04.14 | Holcim buy | UBS AG | |
| 11.04.14 | Holcim buy | UBS AG |
* Die angezeigten Realtime Kurse sind indikativ und nicht die offiziellen Börsenkurse. Die Kursdaten können eventuell vom tatsächlichen Marktpreis abweichen.